Xcout IntelAnkyra Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Ankyra Therapeutics, Inc. among biotechnology companies — ranked by similarity to what Ankyra Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Ankyra Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Ankyra Therapeutics, Inc.
Ankyra Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2019 and headquartered in Cambridge, Massachusetts. The enterprise specializes in developing proprietary anchored cytokine therapies designed to treat various cancers and immune diseases. Its platform technology localizes immune-stimulatory treatments within tumors to maximize therapeutic efficacy while minimizing systemic toxicity.
Ankyra Therapeutics, Inc. at a glance
Ankyra Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $45M in August 2021. Xcout tracks 13 named people at Ankyra Therapeutics, Inc., including Howard L. Kaufman (President and Chief Executive Officer).
Ankyra Therapeutics, Inc. leadership
- Howard L. KaufmanPresident and Chief Executive Officer
- Stephen GorgolChief Financial Officer
- David MauroChief Medical Officer (Fractional)
- Gregory Zarbis-PapastoitsisChief Process and Manufacturing Officer
- Sailaja BattulaChief Scientific Officer
- Tillman GerngrossCo-Founder and Chairman of the Board
7 more named people on record for Ankyra Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Ankyra Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $45M | — | |
| Series B | $45M | 13 named | |
| SEC Form D filing | $14.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Ankyra Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Ankyra Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Actithera, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on delivering targeted radioligand cancer therapies.
Biotech
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Biotech
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Similar biotechnology company
Kanyos Bio, Inc. is a biotechnology company located in Cambridge, Massachusetts, created as a subsidiary of Anokion SA to develop clinical candidates for immune tolerance.
Similar biotechnology company
Angiex Inc. is a private biotechnology company that focuses on novel biology to address the hallmarks of cancer lethality. The firm develops safe and effective cancer therapies and is located in Cambridge, Massachusetts.
Similar biotechnology company
Artax Biopharma, Inc. is a clinical-stage biotechnology company founded in 2013 and headquartered in Cambridge, Massachusetts. The company is focused on transforming the treatment of immune system diseases and recently raised $8 million ahead of a Phase 2a clinical trial.
Similar biotechnology company
Orikine Bio is a biotech company headquartered in Barcelona, Spain, dedicated to advancing engineered cytokines with unique biological features for therapeutic treatments.
Similar biotechnology company
Immunitas Therapeutics, Inc. is a US-based biotechnology company established in 2019 and headquartered in Waltham, Massachusetts. The company focuses on pioneering novel therapeutic treatments in immunology and oncology.
Similar biotechnology company
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
Biotech
Crossbow Therapeutics is a privately held biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company develops potent antibody therapeutics aimed at expanding treatment options and combating cancer.
Similar biotechnology company
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
Biotech
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Ankyra Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Ankyra Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →